Skip to main content
Top
Published in: Acta Diabetologica 12/2019

01-12-2019 | Obesity | Original Article

Timp3 deficiency affects the progression of DEN-related hepatocellular carcinoma during diet-induced obesity in mice

Authors: Viviana Casagrande, Alessandro Mauriello, Lucia Anemona, Maria Mavilio, Giulia Iuliani, Lorenzo De Angelis, Mara D’Onofrio, Ivan Arisi, Massimo Federici, Rossella Menghini

Published in: Acta Diabetologica | Issue 12/2019

Login to get access

Abstract

Aim

Obesity and low-grade inflammation are associated with an increased risk of hepatocellular carcinoma (HCC), a leading cause of cancer-related death worldwide. The tissue inhibitor of metalloproteinase (TIMP) 3, an endogenous inhibitor of protease activity that represents a key mediator of inflammation, is reduced in inflammatory metabolic disorders and cancer. In contrast, Timp3-deficient mice (Timp3−/−) are highly resistant to developing HCC in response to a diethylnitrosamine (DEN); therefore, we aimed to elucidate the biological role of genetic loss of Timp3 in obesity-related hepatocarcinogenesis.

Methods

Fourteen-day-old male wild-type (wt) and Timp3−/− mice were injected with 25 mg/kg DEN or an equal volume of saline. After 4 weeks, mice were randomized into two dietary groups and fed either normal or high-fat diet and allowed to grow until 32 weeks of age. Liver histological features were analyzed, and differentially expressed genes in the liver were quantified.

Results

In Timp3−/− mice fed with the obesogenic diet, despite the increase in liver steatosis and inflammation, both the number of tumors and the total tumor size are significantly reduced 30 weeks post-DEN injection, compared to control mice. Moreover, Timp3 deletion in hepatocarcinogenesis during obesity is associated with a reduction in FoxM1 transcriptional activity through H19/miR-675/p53 pathway.

Conclusions

This study suggests that Timp3 ablation leads to cell cycle perturbation, at least in part by repressing FoxM1 transcriptional activity through H19/miR-675/p53 pathway.
Appendix
Available only for authorised users
Literature
8.
go back to reference Anand-Apte B, Bao L, Smith R et al (1996) A review of tissue inhibitor of metalloproteinases-3(TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 74:853–862CrossRefPubMed Anand-Apte B, Bao L, Smith R et al (1996) A review of tissue inhibitor of metalloproteinases-3(TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 74:853–862CrossRefPubMed
26.
go back to reference Bachman KE, Herman JG, Corn PG et al (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798–802PubMed Bachman KE, Herman JG, Corn PG et al (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798–802PubMed
Metadata
Title
Timp3 deficiency affects the progression of DEN-related hepatocellular carcinoma during diet-induced obesity in mice
Authors
Viviana Casagrande
Alessandro Mauriello
Lucia Anemona
Maria Mavilio
Giulia Iuliani
Lorenzo De Angelis
Mara D’Onofrio
Ivan Arisi
Massimo Federici
Rossella Menghini
Publication date
01-12-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 12/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01382-x

Other articles of this Issue 12/2019

Acta Diabetologica 12/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.